"Dipeptidyl Peptidase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A serine protease that catalyses the release of an N-terminal dipeptide. Several biologically-active peptides have been identified as dipeptidyl peptidase 4 substrates including INCRETINS; NEUROPEPTIDES; and CHEMOKINES. The protein is also found bound to ADENOSINE DEAMINASE on the T-CELL surface and is believed to play a role in T-cell activation.
| Descriptor ID |
D018819
|
| MeSH Number(s) |
D08.811.277.656.350.350.126 D08.811.277.656.959.250 D23.050.301.264.894.160 D23.101.100.894.160
|
| Concept/Terms |
Dipeptidyl Peptidase 4- Dipeptidyl Peptidase 4
- CD26 Antigen
- Antigen, CD26
- Antigens, CD26
- Adenosine Deaminase Complexing Protein 2
- Dipeptidyl-Peptidase IV
- Dipeptidyl Peptidase IV
- CD26 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl Peptidase 4".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl Peptidase 4".
This graph shows the total number of publications written about "Dipeptidyl Peptidase 4" by people in this website by year, and whether "Dipeptidyl Peptidase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 4 | 1 | 5 |
| 2003 | 3 | 0 | 3 |
| 2004 | 0 | 1 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 2 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 2 | 1 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dipeptidyl Peptidase 4" by people in Profiles.
-
Selective refueling of CAR T?cells using ADA1 and CD26 boosts antitumor immunity. Cell Rep Med. 2024 May 21; 5(5):101530.
-
Identification of levomenthol derivatives as potential dipeptidyl peptidase-4 inhibitors: a comparative study with gliptins. J Biomol Struct Dyn. 2024 May; 42(8):4029-4047.
-
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension. 2022 04; 79(4):827-835.
-
Skin Fibrosis and Recovery Is Dependent on Wnt Activation via DPP4. J Invest Dermatol. 2022 06; 142(6):1597-1606.e9.
-
Angiotensin-converting Enzyme 2-containing Small Extracellular Vesicles and Exomeres Bind the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein. Gastroenterology. 2021 02; 160(3):958-961.e3.
-
Determination of immunophenotypic aberrancies provides better assessment of peripheral blood involvement by mycosis fungoides/S?zary syndrome than quantification of CD26- or CD7- CD4+ T-cells. Cytometry B Clin Cytom. 2021 03; 100(2):183-191.
-
Commentary on: Pro-Fibrotic CD26-Positive Fibroblasts Are Present in Greater Abundance in Breast Capsule Tissue of Irradiated Breasts. Aesthet Surg J. 2020 03 23; 40(4):380-382.
-
DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
-
Elevated Human Dipeptidyl Peptidase 4 Expression Reduces the Susceptibility of hDPP4 Transgenic Mice to Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Infect Dis. 2019 02 15; 219(5):829-835.
-
Novel Potentials of the DPP-4 Inhibitor Sitagliptin against Ischemia-Reperfusion (I/R) Injury in Rat Ex-Vivo Heart Model. Int J Mol Sci. 2018 Oct 18; 19(10).